Stoke Therapeutics (STOK) Total Liabilities (2018 - 2026)

Stoke Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $48.4 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 14.81% year-over-year to $48.4 million in Q1 2026; TTM through Mar 2026 was $48.4 million, a 14.81% decrease from a year earlier, with the FY2025 full-year figure at $66.0 million, up 55.12% from the prior year.
• Total Liabilities declined to $48.4 million in Q1 2026 per STOK's latest filing, from $66.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $77.1 million in Q2 2022 and bottomed at $42.5 million in Q4 2024.
• The 5-year median for Total Liabilities is $66.0 million (2025), against an average of $63.2 million.
• Across the five-year window, Total Liabilities surged 351.98% in 2022 and slumped 38.16% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $71.2 million in 2022, then declined by 3.43% to $68.8 million in 2023, then sank by 38.16% to $42.5 million in 2024, then jumped by 55.12% to $66.0 million in 2025, then slipped by 26.64% to $48.4 million in 2026.
• Per Business Quant, the three latest STOK Total Liabilities figures stand at $48.4 million (Q1 2026), $66.0 million (Q4 2025), and $52.2 million (Q3 2025).